Article
Oncology
Qifeng Wang, Lin Peng, Yongtao Han, Tao Li, Wei Dai, Yi Wang, Lei Wu, Yang Wei, Tianpeng Xie, Qiang Fang, Qiang Li, Jinyi Lang, Bangrong Cao
Summary: Low preoperative serum sodium is associated with poor outcome in esophageal carcinoma patients, and may predict survival benefit of adjuvant therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim
Summary: This article reviews established and promising new biomarkers in gastric cancer (GC), including their clinical implications, diagnostic methods, and the efficacy of targeted agents. Comprehensive characterization of the molecular profile and tumor immune microenvironment in GC has enabled researchers to explore promising biomarkers for GC treatment and has introduced a new paradigm in precision-targeted immunotherapy.
Article
Oncology
Jiabin Wang, Qingzhu Qiu, Ningzi Lian, Huagen Wang, Qiaoling Zheng, Yinghong Yang, Yubin Ma, Yajun Zhao, Ping Li, Jianxian Lin, Jun Lu, Qiyue Chen, Longlong Cao, Mi Lin, Changming Huang, Jianwei Xie
Summary: Inhibition of the immune microenvironment is the main cause of tumor recurrence after surgery in patients with gastric cancer. By evaluating immunosuppressive indicators and immune biomarkers, we constructed an immunosuppressive recurrence score and found that it can accurately and reliably predict recurrence. An elevated score is associated with locoregional recurrence and chemotherapy failure.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Naruhiko Ikoma, Jeannelyn S. Estrella, Mariela Blum Murphy, Prajnan Das, Bruce D. Minsky, Paul Mansfield, Jaffer A. Ajani, Brian D. Badgwell
Summary: In gastric cancer patients who underwent preoperative therapy, higher tumor regression grade (TRG) 3 was associated with more advanced ypStage and R1 resection, leading to a shorter overall survival (OS) duration. TRG may be a useful factor for predicting the survival of these patients.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Oncology
Ting Wu, Chun-Hua Wang, Wei Wang, Li-Li Liu, Jing-Ping Yun, Zhi-Wei Zhou
Summary: The study found that gastric cancer patients with normal preoperative CA72-4 have better overall survival and recurrence-free survival. Patients with elevated preoperative and postoperative CA72-4 have a worse prognosis. Routine measurement of both preoperative and postoperative CA72-4 can predict patient outcomes.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma, Tao Peng
Summary: Hepatocellular carcinoma (HCC) is a highly heterogeneous and invasive tumor with unique biological characteristics. Surgical resection and liver transplantation are the main treatment methods, but postoperative recurrence rates are high. This review discusses adjuvant treatment options that may reduce the risk of recurrence and improve overall survival and analyzes potential research directions for changing the paradigm of adjuvant therapy for HCC.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Psychiatry
Hu Liu, Gao Cheng, Yuan-ling Xu, Qi Fang, Lei Ye, Chun-hui Wang, Xue-sheng Liu
Summary: This study revealed significant associations between the pathogenesis of POD after abdominal surgery and the composition of the gut microbiota. Escherichia shigella may serve as promising diagnostic bacterial species for predicting POD onset after abdominal surgery in elderly individuals.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Oncology
Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
Summary: Gastric cancer is a common and deadly disease worldwide. Many patients are diagnosed with unresectable advanced disease due to the ambiguous symptoms. However, some patients have locally advanced gastric cancer (LAGC), which can be treated with surgical resection and perioperative chemotherapy. The optimal treatment for LAGC varies for different subtypes, but promising treatments based on molecular subtypes and biomarkers of LAGC are on the horizon.
Article
Medicine, General & Internal
Ryota Matsui, Noriyuki Inaki, Toshikatsu Tsuji, Ryo Momosaki, Tetsu Fukunaga
Summary: This study investigated whether preoperative low-handgrip strength could predict postoperative outcomes in patients with gastric cancer. The results showed that low-handgrip strength was associated with infectious complications, and chronic kidney disease and diabetes were independent risk factors for infectious complications in patients with low-handgrip strength.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Toshizo Takayama, Yasushi Tsuji
Summary: Surgical resection is the best curative option for gastric cancer, but patients with advanced disease have poor prognosis even after surgery. To reduce the risk of recurrence, perioperative chemotherapy has been combined with surgery, and different standard chemotherapy regimens have been developed in East Asia, Europe, and North America. In recent years, the use of novel agents such as molecular-targeted drugs and immune checkpoint inhibitors in perioperative therapy has shown promising results in these regions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Justin A. Drake, Zachary E. Stiles, Miriam W. Tsao, Jeremiah L. Deneve, Evan S. Glazer, Danny Yakoub, Axel Grothey, Bradley G. Somer, Paxton V. Dickson
Summary: This study demonstrated that only a minority of patients who received preoperative chemotherapy followed by gastric cancer surgery also received postoperative chemotherapy, and the impact on overall survival was limited. Postoperative chemotherapy may benefit patients with N1 disease, but no significant survival benefit was observed for other subgroups. Future trials should focus on determining which patients will benefit from postoperative chemotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Yin Jin, Yilun Xu, Yanyan Li, Renpin Chen, Weiyang Cai
Summary: The study focuses on improving accuracy of prognosis in gastric cancer patients using enhanced computed tomography scanning. Radiogenomics approach combined with survival prediction model can identify candidates who may benefit from ACT, and explore potential drug metabolism mechanisms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yun Gu, Puran Zhang, Jieti Wang, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang
Summary: ARID1A mutation in gastric cancer predicts responsiveness to chemotherapy and immunotherapy, and is associated with DNA damage repair deficiency and immunogenic tumor microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Yusuke Takashima, Shuhei Komatsu, Keiji Nishibeppu, Jun Kiuchi, Takuma Ohashi, Hiroki Shimizu, Tomohiro Arita, Yusuke Yamamoto, Hirotaka Konishi, Ryo Morimura, Atsushi Shiozaki, Yoshiaki Kuriu, Hisashi Ikoma, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji
Summary: The study suggests that a delay of more than 7 weeks in starting adjuvant chemotherapy after surgery can have a negative impact on the prognosis of gastric cancer patients, while a cumulative S-1 dose exceeding 12,000 mg/m(2) may be a key factor in mitigating this negative effect.
Review
Cell Biology
Di Chen, Shuai Ping, Yushuang Xu, Mengmeng Wang, Xin Jiang, Lina Xiong, Li Zhang, Honglu Yu, Zhifan Xiong
Summary: Gastric cancer is a deadly malignancy with largely unknown molecular mechanisms. Recent research has shown that ncRNAs play crucial roles in gastric carcinogenesis, particularly in tumor immune escape, drug resistance, and stemness. Further studies are needed to elucidate the complex relationships between ncRNAs and gastric cancer for clinical applications.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Takahiro Ebata, Kan Yonemori, Tadaaki Nishikawa, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Yasuhiro Fujiwara, Tomoyasu Kato, Kosei Hasegawa, Keiichi Fujiwara, Kenji Tamura
Article
Oncology
Takaaki Mizuno, Yuki Kojima, Kan Yonemori, Hiroshi Yoshida, Yukiko Sugiura, Yohei Ohtake, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Tomoyasu Kato, Tatsunori Shimoi, Masaya Uno, Mitsuya Ishikawa, Yasuhiro Fujiwara, Yuichiro Ohe, Kenji Tamura
Meeting Abstract
Oncology
N. Yamamoto, T. Koyama, M. Nishino, S. Iwasa, S. Kondo, K. Sudo, K. Yonemori, T. Yoshida, K. Tamura, T. Ozaki, M. Kondo, T. Shimizu
ANNALS OF ONCOLOGY
(2020)
Article
Medicine, General & Internal
Rurina Watanuki, Akihiko Shimomura, Shu Yazaki, Shoko Noda-Narita, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Kan Yonemori, Kenji Tamura
Article
Oncology
Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Shigehisa Kitano, Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Kazuki Sudo, Jun Sato, Kenji Tamura, Junichi Tomomatsu, Makiko Ono, Naoki Fukuda, Shunji Takahashi
Summary: This study investigated the use of TAS4464, a potent NEDD8-activating enzyme inhibitor, in patients with advanced solid tumors. The study found that TAS4464 had dose-dependent effects on liver function, which were considered reversible. No complete or partial responses to TAS4464 were observed, but one patient achieved prolonged stable disease.
INVESTIGATIONAL NEW DRUGS
(2021)
Letter
Oncology
Tatsunori Shimoi, Emi Noguchi, Kazuki Sudo, Yu Jo Chua, Kan Yonemori
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
Summary: This study evaluated the efficacy and safety of ONO-4578 as monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors. The results showed that ONO-4578 was well tolerated at the tested doses and showed signs of antitumor activity.
Article
Oncology
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Summary: This study assessed the clinical utility of comprehensive genomic profiling (CGP) tests in advanced or metastatic solid tumor patients, and found that the proportion of patients receiving genomically matched therapy was significantly higher among those with common cancers than non-common cancers.
Article
Oncology
Juntaro Matsuzaki, Ken Kato, Kenta Oono, Naoto Tsuchiya, Kazuki Sudo, Akihiko Shimomura, Kenji Tamura, Sho Shiino, Takayuki Kinoshita, Hiroyuki Daiko, Takeyuki Wada, Hitoshi Katai, Hiroki Ochiai, Yukihide Kanemitsu, Hiroyuki Takamaru, Seiichiro Abe, Yutaka Saito, Narikazu Boku, Shunsuke Kondo, Hideki Ueno, Takuji Okusaka, Kazuaki Shimada, Yuichiro Ohe, Keisuke Asakura, Yukihiro Yoshida, Shun-Ichi Watanabe, Naofumi Asano, Akira Kawai, Makoto Ohno, Yoshitaka Narita, Mitsuya Ishikawa, Tomoyasu Kato, Hiroyuki Fujimoto, Shumpei Niida, Hiromi Sakamoto, Satoko Takizawa, Takuya Akiba, Daisuke Okanohara, Kouya Shiraishi, Takashi Kohno, Fumitaka Takeshita, Hitoshi Nakagama, Nobuyuki Ota, Takahiro Ochiya
Summary: This study demonstrates that large-scale serum miRNomics in combination with machine learning could lead to the development of a blood-based cancer classification system, providing a promising method for noninvasive detection of early-stage cancers.
JNCI CANCER SPECTRUM
(2023)
Article
Oncology
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitoshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori
Summary: Intimal sarcoma is a rare and life-threatening cancer, with most cases exhibiting MDM2 amplification. This study found that the MDM2 inhibitor, Milademetan, showed potential clinical benefits in patients with MDM2-amplified intimal sarcoma. The use of biomarkers such as TWIST1 amplification and CDKN2A loss, as well as sequential liquid biopsy of TP53, could help optimize treatment outcomes.
Article
Oncology
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Summary: The purpose of this study was to determine the recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab for advanced solid tumors and evaluate its safety, efficacy, pharmacokinetics, and biomarker impact. The study found that the combination of E7389-LF and nivolumab was tolerable overall, and the recommended dose for future study was E7389-LF 2.1 mg/m2 and nivolumab 360 mg every 3 weeks.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Ryosuke Saito, Takafumi Kuroda, Hiroshi Yoshida, Kazuki Sudo, Motoaki Saito, Hiroshi Tanabe, Hirokuni Takano, Kyosuke Yamada, Takako Kiyokawa, Kan Yonemori, Tomoyasu Kato, Aikou Okamoto, Takashi Kohno
Summary: The aim of this study was to clarify the clinical, pathological, and genetic characteristics of platinum-sensitive ovarian clear cell carcinomas. The results showed that platinum-sensitive cases had better progression-free and overall survival than platinum-resistant cases. Most platinum-sensitive ovarian clear cell carcinomas lacked the homologous recombination deficiency phenotype, but some cases had ATM mutations.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hisaki Aiba, Yuki Kojima, Tatsunori Shimoi, Kazuki Sudo, Shu Yazaki, Toru Imai, Akihiko Yoshida, Shintaro Iwata, Eisuke Kobayashi, Akira Kawai, Ayumu Arakawa, Chitose Ogawa, Hiroaki Kimura, Kan Yonemori
Summary: Cutaneous/subcutaneous Ewing sarcoma often undergo pre-diagnostic resection without appropriate investigation, but a combination of additional resection and radiotherapy can salvage the local control. This study aimed to analyse the clinical characteristics of patients with cutaneous/subcutaneous Ewing sarcoma and review the treatment strategy. The results showed that patients with cutaneous/subcutaneous Ewing sarcoma may have better prognosis than those with Ewing sarcoma at other anatomical sites.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Shin Ishihara, Koichi Ogura, Aiko Maeshima, Tatsunori Shimoi, Kazuki Sudo, Yuki Kojima, Suguru Fukushima, Shuhei Osaki, Eisuke Kobayashi, Shintaro Iwata, Yoshiyuki Matsui, Kan Yonemori, Akira Kawai
Summary: Peripheral blood immune markers, particularly neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC), have predictive value in assessing the prognosis of soft tissue sarcoma patients treated with eribulin. Low NLR prestart and high ALC8D were associated with longer progression-free survival and overall survival. These findings provide valuable prognostic factors for treatment decisions in the absence of consensus on second-line therapies for STS patients.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Ayumi Saito, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Yuichiro Ohe, Kan Yonemori
Summary: This study found that FR alpha expression is elevated in metastatic tumors of cervical cancer, and high expression is associated with a worse prognosis.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
